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“Off-Label” Stent Therapy
2-Year Comparison of Drug-Eluting Versus Bare-Metal Stents
Robert J. Applegate, MD, FACC, Matthew T. Sacrinty, MPH, Michael A. Kutcher, MD, FACC,
Renato M. Santos, MD, FACC, Sanjay K. Gandhi, MD, FACC, Talal T. Baki, MD, FACC,
William C. Little, MD, FACC
Winston-Salem, North Carolina
Objective The aim was to compare 2-year outcomes with the routine use of drug-eluting stents (DES) (75% “off-label”)
with a comparable group treated with bare-metal stents (BMS).
Background Safety concerns 1 year from implantation have been raised about DES used “off-label.” There are limited data
comparing DES and BMS in “off-label” patients.
Methods Clinical outcomes (nonfatal myocardial infarction [MI], all-cause mortality) were assessed in 1,164 consecutive
patients who received BMS in the year before introduction of DES at Wake Forest University Baptist Medical Cen-
ter and 1,285 consecutive patients who received DES after it became our routine choice. “On-label” stent use
was defined as treatment for a single de novo lesion 30 mm, without recent MI or other major illnesses.
Results At 2 years, the hazard ratio for DES compared with BMS for nonfatal MI or death was 0.77 (95% confidence in-
terval [CI] 0.62 to 0.95), for all-cause mortality 0.71 (0.54 to 0.92), and stent thrombosis (ST) 0.97 (0.49 to
1.91). “On-label” stent procedures were associated with lower risk of MI, death, and ST than “off-label” stent pro-
cedures. For “off-label” stent procedures, the hazard ratio for DES compared with BMS for nonfatal MI or death
was 0.78 (95% CI 0.62 to 0.98), all-cause mortality 0.72 (0.54 to 0.94), and ST 0.91 (0.46 to 1.80). The hazard
of nonfatal MI or death was similar or lower for DES than BMS in high-risk subgroups, including renal failure and
recent MI.
Conclusions The routine clinical use of drug-eluting stents for “off-label” indications was associated with lower nonfatal MI
and death at 2 years than in a comparable group of patients treated with BMS. (J Am Coll Cardiol 2008;51:
607–14) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.064c
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rrug-eluting stents (DES) have reduced the incidence of
ngiographic and clinical restenosis compared with bare-
etal stents (BMS) in randomized clinical trials (RCT) of
ighly selected patients (1,2). This benefit appears to persist
or up to 4 years after stent implantation (3). This has led to
he widespread use of DES, including in patients who
ould not have met the eligibility criteria for inclusion in
See page 615
he RCT of DES versus BMS. However, recent data
uggest that DES may be associated with an increased rate
f late (1 year) stent thrombosis (ST), myocardial infarc-
ion (MI), and death compared with BMS (4–6), particu-
arly in patients not receiving clopidogrel (7). Because of
rom the Section of Cardiology, Wake Forest University School of Medicine.
upported in part by grants from Cordis Corporation and Boston Scientific.D
Manuscript received June 8, 2007; revised manuscript received August 17, 2007,
ccepted August 20, 2007.oncern of adverse late events with DES, the U.S. Food and
rug Administration (FDA) convened a panel to review
vailable data from both pivotal RCT of DES versus BMS
nd post-RCT registry and single-center studies (8,9).
ased on review of these data, the panel concluded that
hen DES were used for their approved indications (“on-
abel”) the risk of late DES thrombosis did not outweigh the
dvantages over BMS in reducing rates of repeat revascu-
arization (10). In contrast, the panel concluded, and the
DA concurred, that adverse late events occurred at a
ufficient incidence to raise concern about the safety of
off-label” DES use (10).
Despite the panel’s conclusions, there are no RCT
omparing outcomes of “on-label” and “off-label” stent
reatments between DES and BMS (9). Moreover, it is
ncertain that an adequately powered clinical trial to eval-
ate these comparisons could be performed or that it would
e representative of the results under the conditions of
outine practice (11). To test the hypothesis that late
ES outcomes may be inferior to BMS when used in
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“Off-Label” DES February 12, 2008:607–14“off-label” stent treatments, we
assessed the clinical outcomes in
consecutive patients treated with
DES when DES utilization was
90% and compared them with
patients who received BMS be-
fore the availability of DES. The
majority (75%) of both stent
groups were “off-label.”
Methods
atients at our institution undergoing percutaneous cor-
nary intervention (PCI) from April 2002 to April 2005
ere included in the study. Of these, 1,164 consecutive
atients, representing all patients who underwent coro-
ary artery stenting between April 2002 and April 2003,
efore FDA approval of DES in the U.S., received BMS
nd served as the control group. The study group
onsisted of 1,285 consecutive patients who received
ES after these stents were fully available (February
004) and had replaced BMS as our routine stents of
hoice (90% utilization). Patients were excluded if they
eceived both BMS and DES (n  8) or were unavailable
or follow up (BMS, n  29; DES, n  35). Patients
ere not excluded from the study for any other reason.
hus, 1,135 BMS and 1,242 DES patients composed the
ontrol and study groups, respectively. The study was
pproved by the Institutional Review Board of Wake
orest University Baptist Medical Center. We previously
eported the 9-month follow-up of most of these patients
12).
Percutaneous coronary intervention was performed ac-
ording to standard techniques. Because sirolimus-eluting
tents were available much earlier than paclitaxel-eluting
tents, they composed most of the DES used in the study:
irolimus-eluting stents, n  971; paclitaxel-eluting stents,
 259; both, n  12. Anticoagulation during PCI was
ccomplished with unfractionated heparin or bivalirudin per
tandard protocol. Patients received glycoprotein IIb/IIIa
eceptor inhibition according to usual protocol with
bciximab or eptifibatide at the discretion of the interven-
ionalist (12). All patients were treated with aspirin (81 to
25 mg/day) before PCI and indefinitely thereafter. Pa-
ients also received clopidogrel (300 to 600 mg as a loading
ose, given before or immediately after the procedure,
ollowed by 75 mg/day). Clopidogrel was given for a
inimum of 1 month in BMS-treated patients, for a
inimum of 3 months for sirolimus-eluting stent–treated
atients, and for a minimum of 6 months for paclitaxel-
luting stent–treated patients. Additional clopidogrel use
as at the discretion of the physician responsible for clinical
are of the patient.
Before hospital discharge, patient and procedural data
nd hospital outcomes were entered into the Wake Forest
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
HR  hazard ratio
MI  myocardial infarction
ST  stent thrombosisniversity Baptist Medical Center Cardiovascular Informa- hion Services Database. Collection of data and outcomes
easures conformed to the American College of Cardiology
ational Cardiovascular Database Registry definitions for
ardiovascular data (13). All patients reported in this study
ad equivalent follow-up duration. Clinical follow-up was
btained as follows: Independent chart review, including
ollow-up visit with a cardiologist, was available for 80% of
atients; scripted phone interviews were obtained for 18% of
atients, who had no clinical follow-up but no reported
ospitalization since their index procedures; and review of
he Social Security Death Index for 2% of patients, where
he death records were the only available follow-up.
ollow-up was censored at 2 years 30 days, with complete
ollow-up available in 95% of BMS and 90% of DES
atients.
Stent thrombosis was defined following the recom-
endations of the Academic Research Consortium
ARC) for definite and probable ST as presentation with
cute coronary syndrome and definite angiographic or
athologic evidence of ST, unexplained death within 30
ays of stent placement, or target vessel infarction in the
bsence of angiography (14). “On-label” stent use was
efined by the study criteria for the initial randomized
ES studies (1,2) as follows: 18 years old, single de
ovo native coronary artery lesions 30 mm in length
ithout thrombus, left ventricular ejection fraction
25%, no MI within 7 days of the procedure, and no
vidence of renal failure (serum creatinine 2.0 mg/dl).
tent use in all other patients was defined as “off-label.”
his definition of “on-label” use is similar to the indica-
ions for both Cypher (Cordis Corporation, Miami,
lorida) and Taxus (Boston Scientific, Billerica, Massa-
husetts), with the exception that renal failure was not
pecifically listed as a contraindication for DES use in the
ndications. Nonfatal MI was defined as ischemic symp-
oms and an elevation of creatine kinase-MB 2 the
pper limit of normal, with or without ST-segment
levation or development of Q waves.
tatistical methods. Descriptive statistics (means and
tandard deviation of continuous factors, frequency
ounts, and relative frequencies of categoric factors) were
alculated and compared using the Wilcoxon rank sum
est for continuous factors and chi-square testing for
ategoric factors. Hazard ratios (HR) are presented along
ith their 95% confidence intervals (CI). Kaplan-Meier
lots of cumulative incidence were constructed from
ndex procedure to 2 years of follow-up. The log rank test
as used to test for differences between DES and BMS
ncidence curves. Cox proportional hazards modeling was
sed to assess independent predictors of outcomes at 2
ears to account for follow-up data censored before 2
ears. The proportional hazards assumption was tested
or all variables by examining log-log survival curves. No
ariables in the final models violated the proportional
azards assumption. The SAS version 9.1 statistical
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February 12, 2008:607–14 “Off-Label” DESoftware package (SAS Institute, Cary, North Carolina)
as used for all statistical analyses.
esults
he baseline clinical characteristics of the BMS and DES
tent groups were similar (Table 1). Acute coronary
yndromes were present overall in 71% of patients, (p 
.23; BMS vs. DES). Procedural characteristics were
imilar with the exception that average length stented was
onger in DES-treated patients, 25  8 mm, compared
ith BMS-treated patients, 20  10 mm; p  0.001. By
tudy design, the baseline characteristics of “on-label”
nd “off-label” patients differed, with more recent MIs,
omorbid illnesses such as renal failure, and multilesion
nd vessel procedures in the “off-label” stent treatments
Table 1). However, within the “on-label” and “off-label”
reatment groups, patient and procedural characteristics
ere similar for BMS and DES. Medication use during
he follow-up period was available for some of the
atients in the study (Table 2). Aspirin was used in 92%
f the BMS patients and 91% of the DES patients; p 
.86 (at 2 years). Clopidogrel use differed between BMS
aseline Clinical and Procedural Characteristics by Stent Type and
Table 1 Baseline Clinical and Procedural Characteristics by Ste
Characteristic
Overall
BMS
(n  1,135)
DES
(n  1,242) p Value
Male gender 66% 65% 0.560
Age, yrs 64  12 63  12 0.154
Heart failure class III or IV 15% 16% 0.504
Current smoker 31% 34% 0.142
Diabetes mellitus 32% 32% 0.696
Hypertension 76% 78% 0.367
Hypercholesterolemia 68% 66% 0.244
Vascular disease 20% 18% 0.216
History of renal failure 5% 6% 0.272
Previous PCI 29% 24% 0.003
Previous CABG 17% 16% 0.478
Indications for procedure
Acute coronary syndrome 70% 73% 0.228
Unstable angina pectoris 33% 32% 0.608
Myocardial infarction 7 days 37% 41% 0.108
Non–ST-segment elevation 18% 23% 0.001
ST-segment elevation 19% 17% 0.159
Stable angina pectoris 26% 23% 0.061
Left ventricular ejection fraction, % 48  16 50  11 0.229
Target lesion vessel
Native coronary artery 93% 95% 0.246
Saphenous vein graft 7% 6% 0.317
Left anterior descending 43% 46% 0.214
Left circumflex 29% 31% 0.478
Right 43% 41% 0.410
Procedure
Number of lesions stented 1.5  0.8 1.4  0.7 0.654
Stented length per lesion, mm 20  10 25  8 0.001
MS  bare-metal stent; CABG  coronary artery bypass grafting; DES  drug-eluting stent; PCInd DES patients, but only at 1 year of follow-up. At 1 hear, clopidogrel use was 40% for BMS and 51% for DES
p  0.001), and at 2 years clopidogrel use was 38% for
MS and 42% for DES (p  0.23). Statin use at 2 years
as 83% for BMS and 85% for DES; p  0.32.
Kaplan-Meier plots of the cumulative incidence of selected
utcomes at 2 years are shown for the entire BMS and DES
roups in Figure 1. The hazard of TVR was lower with DES
ompared with BMS: HR 0.62 (95% CI 0.48 to 0.80). The
ortality curves of the 2 stent groups overlap until approxi-
ately 90 days and then diverge, with a lower hazard of death
n the DES group compared with the BMS group that
ersisted out to 2 years: HR 0.71 (95% CI 0.54 to 0.92).
ortality or nonfatal MI was also lower in the DES patients
ompared with the BMS patients: HR 0.77 (95% CI 0.62 to
.95). Stent thrombosis, however, was similar, with HR 0.97
95% CI 0.49 to 1.91) for DES compared with BMS.
A total of 530 patients (22%) in this study met the criteria
or “on-label” stent use (281 BMS, 249 DES), and the
emaining 1,847 (78%) were “off-label” stent procedures
854 BMS, 993 DES). Cumulative Kaplan-Meier plots of
ncidence of selected outcomes for all 4 groups are shown in
igure 2. Overall, the hazard of nonfatal MI or death was
edure Indication
ype and Procedure Indication
On-Label Off-Label
BMS
 281)
DES
(n  249) p Value
BMS
(n  854)
DES
(n  993) p Value
62% 56% 0.212 68% 68% 0.833
64  11 64  12 0.964 64  12 63  12 0.122
9% 12% 0.236 17% 17% 0.998
29% 29% 0.866 32% 35% 0.106
30% 32% 0.648 33% 31% 0.469
78% 84% 0.083 75% 76% 0.742
77% 70% 0.076 65% 64% 0.857
17% 16% 0.936 21% 18% 0.152
0% 0% — 6% 7% 0.441
32% 27% 0.208 28% 23% 0.010
12% 15% 0.410 18% 16% 0.189
54% 50% 0.285 76% 78% 0.166
54% 50% 0.285 26% 27% 0.435
0% 0% — 50% 51% 0.635
0% 0% — 24% 29% 0.009
0% 0% — 26% 21% 0.029
41% 43% 0.634 21% 18% 0.058
54  9 55  8 0.689 45  17 49  11 0.053
100% 100% — 91% 93% 0.121
0% 0% — 10% 8% 0.157
43% 48% 0.205 44% 45% 0.453
28% 25% 0.302 30% 32% 0.228
29% 27% 0.698 47% 45% 0.229
.0  0 1.0  0 0.999 1.6  0.8 1.5  0.7 0.480
16  5 22  6 0.001 21  11 26  8 0.001
taneous coronary intervention.Proc
nt T
(n
1igher for “off-label” compared with “on-label” stent treat-
m
b
a
D
t
t
f
b
p
a
p
t
b
(
T
t
t
s
C
P
A
610 Applegate et al. JACC Vol. 51, No. 6, 2008
“Off-Label” DES February 12, 2008:607–14ents: HR 2.53 (95% CI 1.80 to 3.57). However, within
oth “on-label” and “off-label” stent treatment groups,
ll-cause mortality and nonfatal MI or death were lower for
ES compared with BMS. For “off-label” stent treatments,
he hazard of nonfatal MI or death was 0.78 (95% CI 0.62
o 0.98) and all-cause mortality 0.72 (95% CI 0.54 to 0.94)
or DES compared with BMS. There were no stent throm-
oses in “on-label” stent treatments during the 2-year study
eriod (Fig. 3). For “off-label” stent treatments, there were
total of 16 stent thromboses in BMS and 17 in DES
Figure 1 Kaplan-Meier Plots of Cumulative Events for BMS and
The number of patients at risk for each follow-up period is given below each graph
stents (DES) than with bare-metal stents (BMS), whereas cumulative stent thro
ost-Index PCI Medications Use by Stent Type and Procedure Indic
Table 2 Post-Index PCI Medications Use by Stent Type and Pro
Medication
Using/
No. Alive n (%)
Overall
BMS DES p Value BMS
Clopidogrel
At 1 month 501/512 (98) 762/773 (99) 0.326 121/126 (
At 1 yr 200/495 (40) 389/760 (51) 0.001 44/122 (
At 2 yrs 186/487 (38) 313/752 (42) 0.229 40/121 (
Aspirin
At 1 month 451/458 (98) 266/274 (97) 0.199 102/103 (
At 1 yr 413/441 (94) 248/261 (95) 0.455 93/99 (
At 2 yrs 397/433 (92) 231/253 (91) 0.862 89/98 (
Statin
1 month 424/508 (83) 627/771 (81) 0.328 105/126 (
At 1 yr 415/491 (85) 636/758 (84) 0.771 102/122 (
At 2 yrs 400/483 (83) 637/750 (85) 0.321 100/121 (
bbreviations as in Table 1.atients; p 0.93. The hazard of ST was 0.91 (95% CI 0.46
o 1.80) for DES compared with BMS. Late stent throm-
oses (1 year) occurred only in “off-label” DES patients
0.8%); Fisher exact test versus “off-label” BMS: p  0.016.
hree of these patients reported taking clopidogrel at the
ime of their DES thrombosis.
Multivariate analysis of ST and nonfatal MI or death for
he entire study population over the 2-year study period is
hown in Table 3. History of renal failure (HR 2.11 [95%
I 1.52 to 2.93]) and diabetes mellitus (HR 1.73 [95% CI
up to 2 Years
verse outcomes were lower with drug-eluting
is rates were similar. MI  myocardial infarction.
re Indication
On-Label Off-Label
DES p Value BMS DES p Value
163/164 (99) 0.089 380/386 (98) 599/609 (98) 0.915
74/164 (45) 0.124 156/373 (42) 315/596 (53) 0.001
61/164 (37) 0.471 146/366 (40) 252/336 (43) 0.366
53/54 (98) 0.999 349/355 (98) 213/220 (97) 0.260
52/54 (96) 0.713 320/342 (94) 196/207 (95) 0.593
49/54 (91) 0.988 308/335 (92) 182/199 (91) 0.844
124/164 (76) 0.110 319/382 (84) 503/607 (83) 0.793
127/164 (77) 0.197 313/369 (85) 509/594 (86) 0.712
135/164 (82) 0.943 300/362 (83) 502/586 (86) 0.247DES
. All ad
mbosation
cedu
96)
36)
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February 12, 2008:607–14 “Off-Label” DES.38 to 2.17]) were 2 of the strongest independent predic-
ors of increased nonfatal MI or death, although DES use
HR 0.75 [95% CI 0.60 to 0.94]) was the strongest
ndependent predictor of lower nonfatal MI or death. The
R of nonfatal MI or death for DES versus BMS were also
ompared across covariate strata (Fig. 4). For almost all of
he clinical and lesion variables assessed, the point estimate
f the HR for nonfatal MI or death favored DES, although
Figure 2 Kaplan-Meier Plots of Cumulative Events up to 2 Year
The number of patients at risk for each follow-up period is given below the graph.
and “off-label” indications, and event rates were lower for “on-label” compared wit
Figure 3 Timing of Stent Thrombosis up to 2 Years
No stent thrombosis occurred with “on-label” indications, although late stent
thrombosis 1 year occurred only with “off-label” DES use. Abbreviations as in
Figure 1.the upper boundaries of the 95% CI crossed the line of
quivalency. The overall HR for nonfatal MI or death
omparing DES with BMS was 0.77 (95% CI 0.62 to 0.95),
avoring DES.
iscussion
n this large contemporary experience comprising mainly
oronary stent procedures classified as “off-label” (9,10), we
bserved a significantly lower hazard of revascularization,
onfatal MI or death, and all-cause mortality at 2 years after
ES compared with BMS. The overall incidence of ST
sing the ARC definition of definite and probable ST (14)
as similar for DES and BMS at 2 years, although the only
ate stent thromboses were observed in “off-label” DES
atients. “On-label” stent treatments were associated with
ewer adverse events at 2 years than “off-label” stent treat-
ents independent of stent type. This observation is con-
istent with the higher-risk baseline and procedural charac-
eristics of patients receiving “off-label” treatments.
owever, “off-label” DES was associated with lower cumu-
ative event rates at 2 years compared with BMS with
quivalent safety (nonfatal MI or death) in spite of a 0.8%
ncidence of late DES thrombosis. Thus, the strategy of
witching to routine use of DES from BMS as evaluated in
“On-Label” and “Off-Label” BMS and DES Indications
erse outcomes were lower with DES than with BMS for both “on-label”
label” indications regardless of stent type. Abbreviations as in Figure 1.s for
All adv
h “off-his study was associated with lower rates of both repeat
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“Off-Label” DES February 12, 2008:607–14evascularization and hard cardiac end points (death and
eath or nonfatal MI).
As discussed previously, the FDA recently convened a
anel amidst growing concerns about DES safety (8). After
eview of available data, however, the panel concluded that
hen DES were used for their approved indications (i.e.,
on-label”), the risk of late DES thrombosis did not
utweigh the advantages over BMS in reducing the rates of
epeat revascularization (10,15). In contrast, the panel
oiced concern of DES safety in patients treated with
igh-risk characteristics (i.e., “off-label” DES use) (9,10)
fter reviewing studies examining outcomes conducted out-
ide of RCT (8,9,16). Other recent studies also have
bserved that high-risk patient and lesion factors con-
ribute to the risk of late ST and nonfatal MI or death
fter DES. However, patients in these studies were drawn
rom study populations consisting exclusively of DES
atients (17,18). Whether the increased relative risk of
ES use in patients with these high-risk features would
e observed compared with a group of patients with
imilar features treated with BMS has not been previ-
usly evaluated (9). Our observations confirm that high-
isk baseline patient and lesion characteristics are associ-
ted with higher rates of late adverse outcomes, regardless
f the type of coronary stent used. However, our analysis
f the relative risk/benefit of DES compared with BMS
n patients with these high-risk features indicated that
se of DES was as safe, if not better, than BMS with
espect to cumulative outcomes in patients in whom these
igh-risk features were present. Longer follow-up of
hese patients will be necessary to determine if continued
ate DES thrombosis occurs and negates the benefits of
ES observed at 2 years.
Stent thrombosis and associated nonfatal MI occur more
han 1 year after stent implantation with DES, but not
MS, after both “on-label” and “off-label” stent procedures
15). However, the reported absolute incidence of these
vents, and their effect on overall outcomes, differs among
Cox PH Multivariate Analysis of Nonfatal MI orto 2 Years
Table 3 Cox PH Multivariate Analysis of Noto 2 Years
Multivariate Model
Nonfatal M
HR (95% CI)
Clinical variables
History of renal failure* 2.11 (1.52–2.93)
Diabetes mellitus 1.73 (1.38–2.17)
MI within 7 days of index PCI 1.71 (1.37–2.14)
Vascular disease 1.66 (1.31–2.10)
Heart failure class III or IV 1.43 (1.10–1.85)
Age, 10 yrs 1.37 (1.23–1.53)
Male gender 1.28 (1.01–1.62)
Drug-eluting stent use 0.75 (0.60–0.94)
No. of lesions stented 1.29 (1.12–1.47)
*No stent thrombosis among renal failure patients, therefore history of
CI  confidence interval; HR  hazard ratio; MI  myocardial infartudies. In the BASKET-LATE (Basel Stent Cost- wffectiveness Trial: Late Clinical Events Related to Late
tent Thrombosis After Stopping Clopidogrel) study, there
as a significantly higher incidence of late (6 months)
T and nonfatal MI with DES than with BMS, although
he cumulative rates of nonfatal MI and death were
imilar for BMS and DES (4). In the SCAARS (Swedish
oronary Angiography and Angiolasty Registry Study),
ortality at 3 years was higher with DES than with BMS
6). In contrast, Tu et al. (19) and the 3-year report of the
-SEARCH (Taxus Stent Evaluated at Rotterdam Car-
iology Hospital) registry (20) both noted lower cumu-
ative event rates with DES than with BMS. The source
f variability of these study observations will likely be the
ubject of intense scrutiny over the next several years as
he safety of DES is evaluated further.
Similar to most recent studies (4 –7), we observed late
T with DES- but not BMS-treated patients. However,
n contrast to some of those studies, the rates of late ST
nd nonfatal MI in the present study were relatively low
nd the cumulative incidence of nonfatal MI or death
fter 2 years were lower for DES than for BMS patients.
he reason for these apparent differences is not clear.
owever, several factors may be important. First, the
-year cumulative incidence of DES thrombosis of 1.5%
n the present study is not statistically different than the
-year DES thrombosis rate of 1.2% reported by Mauri
t al. (14); p  0.41, using the same ARC definition.
econd, the absolute number of late adverse events
ttributable to DES in both the BASKET-LATE study
4) and the Duke Registry (7) were small. Therefore, the
ower to generalize their findings may be limited. Third,
he outcomes of the present study represent the strategy
f using DES for all coronary stent treatments at a time
hen they were fully available and considerable experi-
nce in their implantation had been obtained. In this
anner, we minimized the potential selection bias that
ikely influences the nonrandomized studies comparing
utcomes of patients who were chosen to receive BMS
and Stent Thrombosis
l MI or Death and Stent Thrombosis
eath Stent Thrombosis
p Value HR (95% CI) p Value
0.001
0.001 2.98 (1.43–6.21) 0.003
0.001 1.71 (0.84–3.50) 0.142
0.001 0.55 (0.19–1.60) 0.271
0.007 1.34 (0.57–3.16) 0.504
0.001 0.99 (0.70–1.39) 0.946
0.043 2.10 (0.88–4.98) 0.095
0.011 1.03 (0.49–2.15) 0.943
0.001 1.86 (1.29–2.68) 0.001
ilure was not included in the multivariate model for stent thrombosis.
ther abbreviations as in Table 1.Death
nfata
I or Dith those who received DES. In contrast, the impact of
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February 12, 2008:607–14 “Off-Label” DEShe varied use and experience with DES on study
utcomes that was present in other studies, particularly
he SCAARS, where use of DES ranged from 1% to 60%
n the participating study centers, is uncertain (6). Fi-
ally, we compared DES to a historical, not contempo-
aneous, control group receiving BMS. It is possible that
dvances in medical treatment, such as more aggressive
tatin use and more prolonged use of clopidogrel, may
ave affected the outcomes of this study (7,21,22).
owever, we observed that use of these medications (aspirin,
lopidogrel, and statins) was similar for both BMS- and
ES-treated patients at 2 years. Further study of the effect of
edical treatment on late outcomes merits attention.
The potential mechanism of a lower 2-year cumulative
ncidence of nonfatalMI or death with DESwas not examined
n the present study. Evaluation of the benefit of DES has
Figure 4 Hazard Ratio of Nonfatal MI or Death Comparing BMS
The hazard of nonfatal MI or death was lower for DES use than for BMS use in all
follow-up data before 2 years. †Eight patients did not have history of renal failure
acute coronary syndrome; CHF  congestive heart failure; CI  confidence intervaocused on the ability of this therapy to reduce restenosis. mlthough restenosis is traditionally considered to be a benign
rocess, recent data suggest that restenosis may present as
n MI in up to 9.5% of patients (23,24). Moreover, and
ndependent of the clinical presentation, those receiving
reatment for restenosis have a small incidence of nonfa-
al MI or death in the year following this repeat proce-
ure (25). Our observations support this possibility,
ecause most of the apparent benefit occurred in the first
months after stent implantation, coincident with the
eriod of restenosis vulnerability with BMS. Additional mech-
nisms of benefit may be relevant, such as passivation of
otentially vulnerable plaque owing to stenting of longer
engths of the coronary artery with DES compared with BMS.
owever, further studies will need to be performed to address
hese potential mechanisms.
tudy limitations. Observational studies such as this one
DES by Subgroup
isk subgroups evaluated. *Number of patients who did not have censored
vailable. ‡Seven patients did not have diabetes mellitus data available. ACS 
r abbreviations as in Figure 1.With
high-r
data a
l; otheay be subject to event bias due to unequal follow-up.
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“Off-Label” DES February 12, 2008:607–14owever, we obtained nearly complete follow-up, so that
90% of the patients had follow up available at 2 years. The
resent study may also be confounded by selection bias.
owever, the DES and BMS patients had very similar
aseline clinical and lesion characteristics. Moreover, use of
recent historical control group avoids the potential selec-
ion bias of stent therapies when both BMS and DES are
vailable. Randomized clinical trials would provide the
airest evaluation of DES efficacy and safety, but RCT
sually exclude the very type of high-risk patients that are of
nterest (11). Although there were more than 1,000 patients
n each treatment group, the study was underpowered to
valuate differences in the incidence of ST. Finally, our
tudy did not examine outcomes beyond 2 years. Hopefully,
onger-term follow-up of cohorts such as this will provide
aluable information concerning the relative incidence of late
dverse events after drug-eluting coronary stent treatment.
linical Implications
he observations of lower cumulative rates of nonfatal MI
nd all-cause mortality at 2 years in DES-treated patients
ompared with BMS-treated patients in spite of a low
ncidence of late DES thrombosis is reassuring that use of
ES in routine practice is safe. Moreover, the observa-
ions that “off-label” DES in patients with high-risk
aseline and lesion characteristics were associated with
etter outcomes than with similar patients treated with
MS provide clinical evidence supporting broader, not
ore restricted, use of DES. In spite of the benefits of
ES observed in this study, recent studies raise im-
ortant questions about long-term DES safety in a
roader population of patients than was studied in the
nitial RCT. Longer-term follow-up safety and effective-
ess studies of DES use will need to be obtained to
etermine if late DES-related events will affect the
alance of safety and effectiveness more than 2 years after
ES implantation.
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